Isabella Del Corso
Overview
Explore the profile of Isabella Del Corso including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
10
Citations
108
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Petrelli F, Giannini D, Pucci C, Del Corso I, Rocchi V, Dolcher M, et al.
Int Arch Allergy Immunol
. 2022 Oct;
184(1):54-62.
PMID: 36265449
Introduction: Immediate and delayed hypersensitivity reactions (HSR) to COVID-19 vaccines are rare adverse events that need to be prevented, diagnosed, and managed in order to guarantee adherence to the vaccination...
2.
Petrelli F, Giannini D, Bilia S, Del Corso I, Rocchi V, Migliorini P, et al.
Front Allergy
. 2022 Aug;
3:952079.
PMID: 35935020
Urticarial vasculitis (UV) is a small-vessel leukocytoclastic vasculitis characterized by different clinical manifestations ranging from long-lasting urticarial lesions to severe and potentially life-threatening multi-organ involvement. Omalizumab (OMA), anti-IgE recombinant humanized...
3.
Puxeddu I, Petrelli F, Guerrieri M, Cosio S, Del Corso I, Rocchi V, et al.
Cancers (Basel)
. 2021 Nov;
13(21).
PMID: 34771629
Background: Hypersensitivity reactions (HSR)s to platinum agents are increasing in frequency, due to their extensive use and repeated exposures in patients with increased life expectancy. The aims of our study...
4.
Puxeddu I, Caltran E, Rocchi V, Del Corso I, Tavoni A, Migliorini P
Clin Exp Rheumatol
. 2016 Jan;
34(1):129-32.
PMID: 26751942
The recent development of biological agents, namely, anti-tumour necrosis factor alpha (TNF-α) agents (infliximab, adalimumab and etanercept), anti- CD20 monoclonal antibody (rituximab) and anti-interleukin 6 receptor (IL-6R) monoclonal antibody (tocilizumab),...
5.
Zanichelli A, Arcoleo F, Barca M, Borrelli P, Bova M, Cancian M, et al.
Orphanet J Rare Dis
. 2015 Mar;
10:11.
PMID: 25758562
Introduction: Hereditary angioedema due to C1-inhibitor deficiency (C1-INH-HAE type I) or dysfunction (C1-INH-HAE type II) is a rare disease characterized by recurrent episodes of edema with an estimated frequency of...
6.
Rocchi V, Puxeddu I, Cataldo G, Del Corso I, Tavoni A, Bazzichi L, et al.
Rheumatology (Oxford)
. 2014 Jun;
53(8):1527-9.
PMID: 24899663
No abstract available.
7.
Puxeddu I, Panza F, Pratesi F, Bartaloni D, Casigliani Rabl S, Rocchi V, et al.
Int Arch Allergy Immunol
. 2013 Oct;
162(4):330-4.
PMID: 24157824
Background: Chronic urticaria (CU) is a common disease characterized by recurrent itchy wheals and/or angioedema for more than 6 weeks. We aimed to investigate the potential involvement of chemotactic mediators...
8.
Puxeddu I, Casigliani Rabl S, Panza F, Pratesi F, Rocchi V, Del Corso I, et al.
Arch Dermatol Res
. 2013 Sep;
306(2):197-200.
PMID: 23995607
Chronic urticaria (CU) is a common disease characterized by recurrent itchy wheals and/or angioedema for more than 6 weeks. Increased levels of the pro-angiogenic mediator vascular endothelial growth factor (VEGF)...
9.
Puxeddu I, Giori L, Rocchi V, Bazzichi L, Bombardieri S, Tavoni A, et al.
Ann Allergy Asthma Immunol
. 2012 Feb;
108(2):123-4.
PMID: 22289732
No abstract available.
10.
Free circulating interleukin-18 is increased in Schnitzler syndrome: a new autoinflammatory disease?
Migliorini P, Del Corso I, Tommasi C, Boraschi D
Eur Cytokine Netw
. 2009 Oct;
20(3):108-11.
PMID: 19825519
Schnitzler syndrome is a rare disease characterised by chronic urticaria and arthralgia. The recent evidence that the IL-1 receptor antagonist IL-1Ra could induce rapid and complete remission of Schnitzler symptoms...